Jullian Gabriel Damasceno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jullian Gabriel Damasceno has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Leslie Domenici Kulikowski
Cytogenomics Laboratory, Departament of Pathology, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo 01246-903, Brazil
2 shared publications - Alexandre Torchio Dias
Laboratório de Citogenética, Serviço de Laboratório de Análises Clínicas, Instituto de Assistência Médica do Servidor Público do Estado de São Paulo (IAMSPE), São Paulo, Brasil
1 shared publication - Amanda Cabral da Silva
Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
1 shared publication Amom Mendes Do Nascimento
Laboratório de Citogenômica, Departamento de Patologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo SP, Brazil
1 shared publication- Amom Mendes Nascimento
Laboratório de Citogenômica, Departamento de Patologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brasil
1 shared publication - Aritania Sousa Santos
Laboratório de Carboidratos e Radioimunoensaio (LIM 18), Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo 01246-903, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 27 September 2022
- Published by Springer Nature in Research Square
CitoLIMS: a tool for managing laboratory data for academic laboratory
The diversity of techniques used in an academic research laboratory generates a range of raw data with different formats and information that can exceed 1 gigabyte or terabyte per processing performed. Thus, laboratories need to seek efficient solutions for the management, analysis and curation of your data. The CitoLIMS tool was developed in-house to meet this specific demand and facilitate the secure management of data or analytics published within the scope of academic research in the healthcare field.
- 27 September 2022
- Published by Springer Nature in Research Square
Open AccessCitoLIMS: a tool for managing laboratory data for academic laboratory
The diversity of techniques used in an academic research laboratory generates a range of raw data with different formats and information that can exceed 1 gigabyte or terabyte per processing performed. Thus, laboratories need to seek efficient solutions for the management, analysis and curation of your data. The CitoLIMS tool was developed in-house to meet this specific demand and facilitate the secure management of data or analytics published within the scope of academic research in the healthcare field.
- Open Access
- 19 July 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-15
Progression of Type 1 Diabetes: Circulating MicroRNA Expression Profiles Changes from Preclinical to Overt Disease
Aims/Hypothesis. The role of microRNAs (miRNAs) in type 1 diabetes (T1D) pathogenesis and progression has been described but remains elusive. Objectives. To evaluate the potential biological involvement of miRNA expression in the immune response and beta cell function in T1D. Methods.We screened 377 serum miRNAs of 110 subjects divided into four groups: healthy individuals (control group) and patients at different stages of T1D progression, from the initial immunological manifestation presenting islet autoantibodies (AbP group) until partial and strong beta cell damage in the recent (recent T1D group) and long-term T1D, with 2 to 5 years of disease (T1D 2-5y group).Results. The results revealed 69 differentially expressed miRNAs (DEMs) in relation to controls. Several miRNAs were correlated with islet autoantibodies (IA2A, GADA, and Znt8A), age, and C-peptide levels, mainly from AbP, and recent T1D groups pointing these miRNAs as relevant to T1D pathogenesis and progression. Several miRNAs were related to metabolic derangements, inflammatory pathways, and several other autoimmune diseases. Pathway analysis of putative DEM targets revealed an enrichment in pathways related to metabolic syndrome, inflammatory response, apoptosis and insulin signaling pathways, metabolic derangements, and decreased immunomodulation. One of the miRNAs gene targets was DYRK2 (dual-specificity tyrosine-phosphorylation-regulated kinase 2), which is an autoantigen targeted by an antibody in T1D. ROC curve analysis showed hsa-miR-16 and hsa-miR-200a-3p with AUCs greater than for glucose levels, with discriminating power for T1D prediction greater than glucose levels. Conclusions/Interpretation. Our data suggests a potential influence of DEMs on disease progression from the initial autoimmune lesion up to severe beta cell dysfunction and the role of miRNAs hsa-miR-16 and hsa-miR-200a-3p as biomarkers of T1D progression.
- 19 July 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-15
Open AccessProgression of Type 1 Diabetes: Circulating MicroRNA Expression Profiles Changes from Preclinical to Overt Disease
Aims/Hypothesis. The role of microRNAs (miRNAs) in type 1 diabetes (T1D) pathogenesis and progression has been described but remains elusive. Objectives. To evaluate the potential biological involvement of miRNA expression in the immune response and beta cell function in T1D. Methods.We screened 377 serum miRNAs of 110 subjects divided into four groups: healthy individuals (control group) and patients at different stages of T1D progression, from the initial immunological manifestation presenting islet autoantibodies (AbP group) until partial and strong beta cell damage in the recent (recent T1D group) and long-term T1D, with 2 to 5 years of disease (T1D 2-5y group).Results. The results revealed 69 differentially expressed miRNAs (DEMs) in relation to controls. Several miRNAs were correlated with islet autoantibodies (IA2A, GADA, and Znt8A), age, and C-peptide levels, mainly from AbP, and recent T1D groups pointing these miRNAs as relevant to T1D pathogenesis and progression. Several miRNAs were related to metabolic derangements, inflammatory pathways, and several other autoimmune diseases. Pathway analysis of putative DEM targets revealed an enrichment in pathways related to metabolic syndrome, inflammatory response, apoptosis and insulin signaling pathways, metabolic derangements, and decreased immunomodulation. One of the miRNAs gene targets was DYRK2 (dual-specificity tyrosine-phosphorylation-regulated kinase 2), which is an autoantigen targeted by an antibody in T1D. ROC curve analysis showed hsa-miR-16 and hsa-miR-200a-3p with AUCs greater than for glucose levels, with discriminating power for T1D prediction greater than glucose levels. Conclusions/Interpretation. Our data suggests a potential influence of DEMs on disease progression from the initial autoimmune lesion up to severe beta cell dysfunction and the role of miRNAs hsa-miR-16 and hsa-miR-200a-3p as biomarkers of T1D progression.
- Open Access
- 30 September 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (2) , e957
Breakpoint delineation in 5p‐ patients leads to new insights about microcephaly and the typical high‐pitched cry
Background: Cri du chat syndrome (CdCS) is a rare syndrome caused by a partial or complete deletion of the short arm of chromosome 5 (5p‐). The main clinical features include a high‐pitched cry, facial asymmetry, microcephaly, round face at birth, epicanthal folds, hypotonia, delayed growth and development.Methods: We studied 14 Brazilian patients with CdCS using genomic array in order to better define the 5p breakpoints and recognize copy number variations (CNVs) that contribute to clinical manifestations associated with the syndrome.Results: Array confirmed terminal deletions in 13 patients and an interstitial deletion in one patient. It was also possible to map the breakpoints and associate a genomic region of 4.7 Mb to the development of head circumference and cat‐like cry. We also found other CNVs concomitant to the 5p deletion including a 9p duplication, a 17q deletion, and a 22q deletion in three different patients.Conclusion: With advancements of molecular cytogenomic methods in the last two decades, it was possible to evidence cryptic alterations and improve the genotype–phenotype correlation. In this work, we describe a new genomic region associated with microcephaly and cat‐like cry and highlight the importance of precise delineation of 5p deletion breakpoints and detection of other CNVs in CdCS patients to improve genotype–phenotype correlation to perform a complete clinical and molecular diagnosis.
- 30 September 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (2) , e957
Open AccessBreakpoint delineation in 5p‐ patients leads to new insights about microcephaly and the typical high‐pitched cry
Background: Cri du chat syndrome (CdCS) is a rare syndrome caused by a partial or complete deletion of the short arm of chromosome 5 (5p‐). The main clinical features include a high‐pitched cry, facial asymmetry, microcephaly, round face at birth, epicanthal folds, hypotonia, delayed growth and development.Methods: We studied 14 Brazilian patients with CdCS using genomic array in order to better define the 5p breakpoints and recognize copy number variations (CNVs) that contribute to clinical manifestations associated with the syndrome.Results: Array confirmed terminal deletions in 13 patients and an interstitial deletion in one patient. It was also possible to map the breakpoints and associate a genomic region of 4.7 Mb to the development of head circumference and cat‐like cry. We also found other CNVs concomitant to the 5p deletion including a 9p duplication, a 17q deletion, and a 22q deletion in three different patients.Conclusion: With advancements of molecular cytogenomic methods in the last two decades, it was possible to evidence cryptic alterations and improve the genotype–phenotype correlation. In this work, we describe a new genomic region associated with microcephaly and cat‐like cry and highlight the importance of precise delineation of 5p deletion breakpoints and detection of other CNVs in CdCS patients to improve genotype–phenotype correlation to perform a complete clinical and molecular diagnosis.